GLP-1 drugs plus lifestyle counseling achieve top weight loss in youth

A systematic review and network meta‑analysis of 42 randomized trials involving 3,835 participants found that the GLP‑1 receptor agonist semaglutide combined with counseling produced the greatest reductions in body‑mass index (BMI) and BMI‑z score among children and teenagers with obesity. Pharmacotherapy paired with intensive lifestyle treatment was linked with the most substantial short‑term weight loss, while lifestyle interventions alone also yielded meaningful BMI decreases compared with no structured program.

Separate evidence indicates that users of GLP‑1 weight‑loss medications often reduce their physical activity; about 38% reported a decline in exercise within six months, and clinicians note lower energy levels and less motivation for movement. Guidelines call for these drugs to be part of a broader treatment plan that includes exercise counseling, yet many primary‑care physicians do not consistently provide such guidance. The combined findings highlight the importance of integrating lifestyle counseling with GLP‑1 therapy to maximise weight‑loss benefits while mitigating sedentary risks.